Literature DB >> 23921514

Platelet ITAM signaling.

Wolfgang Bergmeier1, Lucia Stefanini.   

Abstract

PURPOSE OF REVIEW: G protein-coupled receptors (GPCRs) like PAR1/4 and P2Y12 have long been known for their critical role in hemostasis. In contrast, deficiency in the immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors glycoprotein (GP)VI or C-type lectin-like receptor (CLEC)-2 is associated with only a mild bleeding diathesis in humans and mice. This review summarizes recent developments on the physiological importance of platelet ITAM signaling as well as the molecular mechanisms facilitating this signaling pathway. RECENT
FINDINGS: Genetic experiments identified a critical role for platelet CLEC-2 signaling in the formation of lymphatic vessels during development. Similarly, signaling by both GPVI and CLEC-2, but not GPCRs, is required for the maintenance of vascular integrity at sites of inflammation in the adult. The molecular mechanisms underlying ITAM signaling in platelets continue to be refined.
SUMMARY: Platelet ITAM signaling plays a key role for the maintenance of vascular integrity in development and the adult. This novel form of hemostasis differs from hemostasis at sites of vascular injury in that it does not depend on major platelet adhesion receptors or GPCR signaling.

Entities:  

Mesh:

Year:  2013        PMID: 23921514     DOI: 10.1097/MOH.0b013e3283642267

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  21 in total

1.  CLEC-2 expression is maintained on activated platelets and on platelet microparticles.

Authors:  Eelo Gitz; Alice Y Pollitt; Jerney J Gitz-Francois; Osama Alshehri; Jun Mori; Samantha Montague; Gerard B Nash; Michael R Douglas; Elizabeth E Gardiner; Robert K Andrews; Christopher D Buckley; Paul Harrison; Steve P Watson
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

2.  TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Authors:  S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

3.  CLEC-2: the inside story.

Authors:  Debra K Newman
Journal:  Blood       Date:  2015-06-25       Impact factor: 22.113

Review 4.  Platelet "first responders" in wound response, cancer, and metastasis.

Authors:  David G Menter; Scott Kopetz; Ernest Hawk; Anil K Sood; Jonathan M Loree; Paolo Gresele; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

5.  Self-control of platelets: a new ITIM story.

Authors:  Xiaoping Du
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

Review 6.  Update on the role of endothelial cells in trauma.

Authors:  J Greven; R Pfeifer; Q Zhi; H C Pape
Journal:  Eur J Trauma Emerg Surg       Date:  2017-07-03       Impact factor: 3.693

7.  Differential Roles of the NADPH-Oxidase 1 and 2 in Platelet Activation and Thrombosis.

Authors:  M Keegan Delaney; Kyungho Kim; Brian Estevez; Zheng Xu; Aleksandra Stojanovic-Terpo; Bo Shen; Masuko Ushio-Fukai; Jaehyung Cho; Xiaoping Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-17       Impact factor: 8.311

Review 8.  Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Authors:  Jennifer Yeung; Wenjie Li; Michael Holinstat
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

9.  Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation.

Authors:  Jennifer Yeung; Benjamin E Tourdot; Pilar Fernandez-Perez; Joanne Vesci; Jin Ren; Christopher J Smyrniotis; Diane K Luci; Ajit Jadhav; Anton Simeonov; David J Maloney; Theodore R Holman; Steven E McKenzie; Michael Holinstat
Journal:  Blood       Date:  2014-08-06       Impact factor: 22.113

10.  CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexes.

Authors:  A Amirkhosravi; Y Boulaftali; L Robles-Carrillo; T Meyer; S E McKenzie; J L Francis; W Bergmeier
Journal:  J Thromb Haemost       Date:  2014-10-30       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.